ReachMD

Episodes 31-45 of 89

• 

  RestartResume

  What is the Recommended Monitoring Plan for Patients Receiving RET-Targeted Therapies?

  Minute CME/CE™

  What is the Recommended Monitoring Plan for Patients Receiving RET-Targeted Therapies?

  • 

    

    Justin Gainor, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Selecting and Managing RET-Targeted Therapy in mNSCLC

  Minute CME/CE™

  Selecting and Managing RET-Targeted Therapy in mNSCLC

  • 

    

    Justin Gainor, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  1.00 program credits

• 

  Minute CME/CE™

  REThink Treatment of NSCLC: Optimizing Care Through Early Genomic Testing and Targeted Treatment

  • 

    

    Justin Gainor, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  1.00 credits 7 episodes

• 

  RestartResume

  Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers

  Minute CME/CE™

  Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers

  • 

    

    Alexander Drilon, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

  Minute CME/CE™

  Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

  • 

    

    Alexander Drilon, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Side-Effects of RET-Directed Targeted Therapy

  Minute CME/CE™

  Side-Effects of RET-Directed Targeted Therapy

  • 

    

    Alexander Drilon, MD

    Peer

  1.00 program credits

• 

  RestartResume

  TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use

  CME/CE

  TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use

  • 

    

    Benjamin Levy, MD

    Peer

  • 

    

    Rebecca Heist, MD, MPH

    Peer

  • 

    

    Peter Bela Illei, MD

    Peer

  0.50 credits

• 

  RestartResume

  Evaluating Your Current Options in the Treatment of NSCLC with METex14 Skipping Mutations

  CME/CE

  Evaluating Your Current Options in the Treatment of NSCLC with METex14 Skipping Mutations

  • 

    

    Paul Paik, MD

    Peer

  • 

    

    Catherine Shu, MD

    Peer

  0.25 credits

• 

  RestartResume

  Patient-Centered Discussions and Shared Decision-Making in the Management of NSCLC with METex14 Skipping Mutations

  CME/CE

  Patient-Centered Discussions and Shared Decision-Making in the Management of NSCLC with METex14 Skipping Mutations

  • 

    

    Jyoti D. Patel, MD, FASCO

    Peer

  0.25 credits

• 

  RestartResume

  Prosecution’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Minute CME/CE™

  Prosecution’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Alexander Opotowsky, MD, MMSc

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  1.00 program credits

• 

  Minute CME/CE™

  Holding Court in Pulmonary Hypertension: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy?

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jean M. Elwing, MD

    Peer

  • 

    

    Wayne J. Franklin, MD, FACC

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Alexander Opotowsky, MD, MMSc

    Peer

  1.00 credits 4 episodes

• 

  RestartResume

  Closing Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Minute CME/CE™

  Closing Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Defense’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Minute CME/CE™

  Defense’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  • 

    

    Joseph Kay, MD

    Peer

  • 

    

    Wayne J. Franklin, MD, FACC

    Peer

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Opening Statements - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Minute CME/CE™

  Opening Statements - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  • 

    

    Jean M. Elwing, MD

    Peer

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Navigating Symptom Reporting Variability by Patients with Chronic Cough

  Minute CME/CE™

  Navigating Symptom Reporting Variability by Patients with Chronic Cough

  • 

    

    Peter Dicpinigaitis, MD

    Peer

  • 

    

    Michael Blaiss, MD

    Peer

  • 

    

    Rachel M. Taliercio, DO

    Peer

  1.50 program credits

• Prev
• 1
• 2
• 3
• 4
• 5
• 6
• Next